Day two at the American Heart Association meeting featured the latest findings from researchers for the Physicians' Health Study II and promising, but very early results, from a study of an investigational lipid-lowering antibody treatment, a pair of findings highlighted in this exclusive InFocus video report.
Harvard's Elliott Antman, MD, who chaired the scientific program here, said it is not surprising that daily vitamin therapy did not reduce the risk of cardiovascular events in a population of healthy men, who also happen to be physicians. And, he noted, that the same researchers recently reported that the daily vitamins did slightly reduce the risk for developing cancer.
More promising findings came from studies of an investigational antibody treatment for dyslipidemia -- a PCSK9 inhibitor known now as AMG 145 -- that achieved significant reductions in LDL among patients who can't tolerate statin therapy and those with heterozygous familial hypercholesterolemia. The antibody treatment is given subcutaneously and that may present a challenge, Antman told Peggy Peck, MedPage Today Editor-in-Chief.
From the American Heart Association:
No hay comentarios:
Publicar un comentario